Actavis upgraded to Positive from Neutral at Susquehanna

theflyonthewall.com

Susquehanna upgraded Actavis (ACT) to Positive from Neutral based on valuation and increased confidence in the Forest Labs (FRX) deal. Price target raised to $260 from $200.

View Comments (0)